Alisha Badal is addressing the challenges of treating aggressive triple-negative breast cancers (TNBC) with BRCA mutations by proposing a strategy that involves molecular gene editing to upregulate a downregulated long-noncoding RNA (lncRNA) gene. This innovative approach aims to restore aberrant regulatory networks in TNBC, testing the synergistic efficacy of a metallotherapy apoptosis agent and a DNA repair inhibitor, offering potential new treatment options for this challenging form of breast cancer.
Falling Walls
Falling Walls Science Summit 2023
Login or Register
You need to be logged in to use this feature.
Breaking the Wall of Limited Cancer Treatment
Alisha Badal is pursuing a PhD in molecular and cell biology at the University of the Witwatersrand. Her research aims to incorporate advanced molecular gene editing techniques to enhance the efficacy of targeted anti-cancer drugs to treat triple-negative breast cancer. A significant component of her research focuses on the development of a Silver(I) phosphine complex as a novel anti-cancer drug to activate apoptosis cell death in breast cancer with high efficacy and safety. She has a MSc in molecular and cell biology from the University of the Witwatersrand and a BSc in biochemistry and human physiology from the University of Johannesburg.
Further Activities to have a look at